8828427

Celgene sued Dr. Reddy's in an ANDA/Hatch-Waxman action concerning pomalidomide (POMALYST®) patents, including U.S. Pat. Nos. 8,198,262; 8,735,428; 8,828,427; and 9,993,467. The narrative states that US3845770 does not appear to have been asserted in this case, despite its association with the patent-page litigation listing. Final judgment was entered on February 23, 2022.

Hatch-Waxman ANDA litigation. The '427 was expressly named among the patents-in-suit, but Celgene withdrew its '427 infringement claims. Consolidated/coordinated for claim construction with 17-cv-03159. Case terminated 2021-08-19.

Hatch-Waxman ANDA litigation. Consolidated for claim construction with 17-cv-03387. Terminated around 2019-02-06.

Hatch-Waxman ANDA litigation. Consent judgment entered June 15, 2022 (Judge Esther Salas): permanent injunction; all claims/counterclaims dismissed with prejudice. Patents-in-suit expressly included 8,828,427 plus '262, '939, '428, '467, '5939.

Hatch-Waxman ANDA litigation concerning Sandoz ANDA No. 220741. Consent judgment Nov. 17, 2025: permanent injunction barring Sandoz's ANDA product until expiration of patents-in-suit; § 271(e)(1) and Paragraph IV rights expressly preserved.

Hatch-Waxman ANDA litigation concerning Cipla ANDA No. 219718 (1/2/3/4 mg). Consent judgment entered Sept. 11, 2025; case closed Sept. 17, 2025. Patents-in-suit: 8,828,427; 9,993,467; 10,555,939. Injunction until expiration; no damages.

Hatch-Waxman ANDA litigation filed after Dr. Reddy's ANDA (Mar. 29, 2019) and Paragraph IV notice (May 31, 2019); asserted '262, '3939, '428, '427, and '467. Outcome not confirmed in the sources reviewed.

Docket number listed on the '427 patent's family-litigation record as a Celgene pomalidomide ANDA matter; parties/outcome not confirmed.

Identified in the Cigna complaint as Celgene Corp. v. Mylan; opinion at 2020 WL 12570814 (D.N.J. Sept. 25, 2020) granted Mylan's motion to dismiss for improper venue.

Follow-on antitrust suit alleging Sherman Act § 2 monopolization. Complaint alleges the '427 was expressly taught in prior art and issued after a purportedly false Tutino Declaration, and that Celgene withdrew its '427 infringement claims before most settlements.

Lead consolidated case for Celgene's pomalidomide ANDA litigation against Hetero; many earlier generic ANDA cases were consolidated into this case.

Celgene's 2018 ANDA infringement case against an unidentified generic pomalidomide filer; consolidated into lead case 17-cv-3387 by Consolidation Order on 2019-01-31.

Celgene's ANDA infringement suit against Apotex; docket shows civil case terminated on 2019-02-08 upon consolidation into lead case 17-cv-3387.

Celgene's 2025 pomalidomide ANDA infringement suit against USV Private Limited; listed as remaining open.

Federal Circuit appeal of the 2:19-cv-05802 venue dismissal; affirmed on Nov. 5, 2021, holding Mylan lacked a regular and established place of business in New Jersey and that the ANDA submission, not the paragraph IV notice letter, is the operative infringing act.

Celgene filed a § 271 patent infringement action against Synthon in M.D.N.C. asserting US 8,198,262, 8,673,939, 8,735,428, and 8,828,427. The case was terminated July 25, 2018 by a stipulation of dismissal, described as a parallel/companion filing to the New Jersey action.

Hatch-Waxman ANDA patent-infringement suit involving pomalidomide (ANDA No. 213234). Patents asserted included U.S. 8,198,262, 8,673,939, 8,735,428, 8,828,427, and U.S. 9,993,467. A consent judgment enjoined Dr. Reddy's from infringing the patents-in-suit until expiration and dismissed all claims, counterclaims, and defenses with prejudice.